<DOC>
	<DOCNO>NCT02044419</DOCNO>
	<brief_summary>To compare relative bioavailability lomitapide administer sprinkle content 20 mg capsule lomitapide applesauce mash banana single oral intact capsule dose 20 mg lomitapide healthy subject .</brief_summary>
	<brief_title>A Comparative Bioavailability Study Lomitapide 20 mg Intact v Sprinkled</brief_title>
	<detailed_description />
	<criteria>1 . Subject nonsmoking healthy male female , age 18 40 year age . 2 . Subject BMI 18.5 25 kg/m2 . 3 . Subject total body weight &gt; 50 kg â‰¤ 100 kg . 4 . Subjects must agree use acceptable method contraception . 5 . All female , regardless childbearing potential , must negative serum beta human chorionic gonadotropin pregnancy test Screening admission . 6 . In good health , determine clinically significant relevant abnormality identify detailed medical history &amp; full physical examination . 7 . No known history hypersensitivity previous intolerance lomitapide , applesauce , and/or banana . 8 . Subjects must capable understand comply requirement protocol must sign informed consent form prior undergoing studyrelated procedure . 1 . Subject clinically significant disease condition disease might affect drug absorption , distribution excretion . 2 . History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug . 3 . Any clinically significant abnormal laboratory , vital sign safety finding determine medical history , physical examination evaluation . 4 . History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator ; 5 . Electrocardiogram ( ECG ) abnormalities standard 12lead ECG ( screen ) QTcF interval &gt; 450 msec , history prolong QTc interval Brugada syndrome . 6 . History current evidence clinically relevant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , haematological , endocrinological , allergic , dermatological , metabolic , neurological , psychiatric disease . 7 . History laboratory evidence Gilbert 's syndrome . 8 . Positive result serology test Hepatitis B Surface Antigen ( HbsAg ) , antiHepatitis core antibody ( antiHBc Ig G [ antiHBc IgM IgG positive ] , Hepatitis C antibody ( antiHCV ) , HIV 1 2 antibody , ( antiHIV 1/2 ) . 9 . Use drug abuse within 6 month prior admission . 10 . Confirmed positive result urine drug screen ( amphetamine , benzodiazepine , cocaine , cannabinoids , opiate , barbiturates methadone ) alcohol breath test screen admission ( Day 1 ) . 11 . History clinical evidence alcohol drug abuse within one year prior admission . 12 . Mentally handicap . 13 . Participation drug trial within 90 day prior first drug administration . 14 . Use prescription medication within 2 week prior admission ( Day 1 ) , exception oral contraceptive pill . 15 . Use substance induce inhibit CYP3A4 enzyme within 30 day prior admission ( Day 1 ) . 16 . Use overthecounter ( OTC ) medication ( include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation ) within 7 day prior admission ( Day 1 ) , unless deem acceptable Investigator Sponsor . 17 . Use alcohol , grapefruit , starfruit , caffeinecontaining food beverage within 72 hour prior admission Study Completion . 18 . Donation 500 mL blood within 90 day prior drug administration . 19 . Receipt blood product within 2 month prior admission . 20 . Poor peripheral venous access . 21 . Use tobacco nicotinecontaining product ( within 6 month prior admission ( Day 1 ) . 22 . Any acute chronic condition , schedule hospitalisation ( inclusive elective surgery study ) , schedule travel prior completion study procedure . 23 . Any circumstance condition , , opinion PI , may affect full participation trial compliance protocol . 24 . Legal incapacity limit legal capacity screening . 25 . Subjects vegetarian , vegan dietary restriction conflict study standardise menu .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Comparative</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>lomitapide</keyword>
</DOC>